MiNK Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2020 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
MiNK Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2020 to 2023.
  • MiNK Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$3.07M, a 51.6% increase year-over-year.
  • MiNK Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$17.6M, a 37.2% increase year-over-year.
  • MiNK Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$22.9M, a 25.9% increase from 2022.
  • MiNK Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$30.9M, a 9.14% decline from 2021.
  • MiNK Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$28.4M, a 93.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$22.9M +$8.03M +25.9% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-21
2022 -$30.9M -$2.59M -9.14% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-21
2021 -$28.4M -$13.7M -93.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-24
2020 -$14.6M Jan 1, 2020 Dec 31, 2020 10-K 2022-03-18
* An asterisk sign (*) next to the value indicates that the value is likely invalid.